Referral Center for Myocardial Diseases, Cytogenetics Unit and Department of Clinical Physiopathology, and Nuclear Medicine Unit, Careggi University Hospital, Florence, Italy.
J Am Coll Cardiol. 2011 Aug 16;58(8):839-48. doi: 10.1016/j.jacc.2011.05.018.
The purpose of this study was to assess myocardial blood flow (MBF) using positron emission tomography in patients with hypertrophic cardiomyopathy (HCM) according to genetic status.
Coronary microvascular dysfunction is an important feature of HCM, associated with ventricular remodeling and heart failure. We recently demonstrated the increased prevalence of systolic dysfunction in patients with HCM with sarcomere myofilament gene mutations and postulated an association between genetic status and coronary microvascular dysfunction.
Maximum MBF (intravenous dipyridamole, 0.56 mg/kg; Dip-MBF) was measured using (13)N-labeled ammonia in 61 patients with HCM (age 38 ± 14 years), genotyped by automatic DNA sequencing of 8 myofilament-encoding genes (myosin-binding protein C, beta-myosin heavy chain, regulatory and essential light chains, troponin T, troponin I, troponin C, alpha-tropomyosin, and alpha-actin). In 35 patients, cardiac magnetic resonance imaging was performed.
Fifty-three mutations were identified in 42 of the 61 patients (genotype positive; 69%). Despite similar clinical profiles, genotype-positive patients with HCM showed substantially lower Dip-MBF compared with that of genotype-negative patients (1.7 ± 0.6 ml/min/g vs. 2.4 ± 1.2 ml/min/g; p < 0.02). A Dip-MBF <1.5 ml/min/g had 81% positive predictive value for genotype-positive status and implied a 3.5-fold independent increase in likelihood of carrying myofilament gene mutations (hazard ratio: 3.52; 95% confidence interval: 1.05 to 11.7; p = 0.04). At cardiac magnetic resonance imaging, the prevalence of late gadolinium enhancement was greater in genotype-positive patients (22 of 23 [96%] compared with 8 of 12 [67%] genotype-negative patients; p = 0.038).
Patients with HCM with sarcomere myofilament mutations are characterized by more severe impairment of microvascular function and increased prevalence of myocardial fibrosis, compared with genotype-negative individuals. These findings suggest a direct link between sarcomere gene mutations and adverse remodeling of the microcirculation in HCM, accounting for the increased long-term prevalence of ventricular dysfunction and heart failure in genotype-positive patients.
本研究旨在根据基因状态评估肥厚型心肌病(HCM)患者的心肌血流(MBF)。
冠状动脉微血管功能障碍是 HCM 的一个重要特征,与心室重构和心力衰竭有关。我们最近发现,肌球蛋白结合蛋白 C、β-肌球蛋白重链、调节和必需轻链、肌钙蛋白 T、肌钙蛋白 I、肌钙蛋白 C、α-原肌球蛋白和α-肌动蛋白)。在 35 名患者中进行了心脏磁共振成像。
在 61 名 HCM 患者(年龄 38 ± 14 岁)中,通过自动 DNA 测序鉴定出 8 个肌球蛋白编码基因中的 53 个突变(基因型阳性;69%)。尽管临床特征相似,但基因型阳性的 HCM 患者的 Dip-MBF 明显低于基因型阴性患者(1.7 ± 0.6 ml/min/g 比 2.4 ± 1.2 ml/min/g;p < 0.02)。Dip-MBF <1.5 ml/min/g 对基因型阳性状态的阳性预测值为 81%,提示携带肌球蛋白基因突变的可能性增加了 3.5 倍(危险比:3.52;95%置信区间:1.05 至 11.7;p = 0.04)。在心脏磁共振成像中,基因型阳性患者的晚期钆增强发生率更高(23 例中有 22 例[96%],而基因型阴性患者中有 12 例中的 8 例[67%];p = 0.038)。
与基因型阴性个体相比,肌球蛋白基因突变的 HCM 患者的微血管功能障碍更为严重,心肌纤维化的发生率更高。这些发现表明,肌节基因突变与 HCM 微循环的不良重构之间存在直接联系,这可以解释基因型阳性患者心室功能障碍和心力衰竭的长期发生率增加。